Inflammation

Q32 Bio concludes merger deal with Homology Medicines

Clinical stage biotechnology company Q32 Bio has announced the conclusion of its merger with Homology Medicines, for an undisclosed sum.

AOB Pharma, Maruho partner to develop B244 for inflammatory ailments

AOB Pharma has signed an exclusive license and development agreement with Maruho for the development and marketing of its topical biologic, B244, for inflammatory indications in Japan.

Sandoz makes available biosimilar of Humira in US

Novartis subsidiary Sandoz has made available a citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz) injection, a biosimilar of Humira (adalimumab), in the United States (US).

Rani, Celltrion expand partnership for development of adalimumab biosimilar

Rani Therapeutics has expanded its collaboration with Celltrion for developing RT-105, an orally administered adalimumab biosimilar.

Graybug, CalciMedica sign agreement to create new biopharmaceutical company

Graybug Vision and CalciMedica have signed a definitive merger agreement to create a new clinical-stage biopharmaceutical company.

Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis 

Galapagos has obtained marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Jyseleca (filgotinib 200mg tablets) to treat ulcerative colitis (UC) in Great Britain.

US DOD to fund Humanetics’ new drug test against Covid-19

The US Department of Defense (DOD) has approved the funding of US-based private pharmaceutical firm Humanetics to test its drug candidate BIO 300 in treating pulmonary inflammation triggered by COVID-19.